CSBA Letter to Congressional Leaders urging for passage of S. 866, the American Innovation & Jobs Act of 2023 (March 28, 2023)

March 30, 2023

Download Full Comments Below

csba_letter_to_congressional_leaders_urging_for_passage_of_s._866_the_american_innovation_jobs_act_of_2023_march_28_2023.pdf

Download

Discover More

BIO Comments to FDA (Docket No. FDA-2023-N-0398)…

In these comments, BIO addresses FDA’s four specific topic areas of consideration as the agency develops its draft guidance per PDUFA VII.

Learn more

Letter in support of U.S. Codex Office funding

BIO joined with more than 40 groups in calling on Congress to set 2024 funding for the U.S. Codex Office at or above the 2023 level.

Learn more

BIO Comments to the FDA on Clinical Trial…

BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.

Learn more